Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma

• Published in: Blood advances Vol. 7; no. 5; pp. 768 - 777
• Main Authors: Frigault, Matthew J., Bishop, Michael R., Rosenblatt, Jacalyn, O’Donnell, Elizabeth K., Raje, Noopur, Cook, Daniella, Yee, Andrew J., Logan, Emma, Avigan, David E., Jakubowiak, Andrzej, Shaw, Kit, Daley, Heather, Nikiforow, Sarah, Griffin, Faith, Cornwell, Christine, Shen, Angela, Heery, Christopher, Maus, Marcela V.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 14.03.2023; The American Society of Hematology
• Subjects: Clinical Trials and Observations; Humans; Lymphocytes; Multiple Myeloma - drug therapy; Neurotoxicity Syndromes; Receptors, Chimeric Antigen - therapeutic use

•CART-ddBCMAs are safe for use in patients with relapsed or refractory multiple myeloma.•CART-ddBCMAs produce deep and durable responses in patients with poor prognostic factors. [Display omitted] Relapsed and refractory multiple myeloma (RRMM) is a plasma cell neoplasm defined by progressively refr...